During 2021, Drug Delivery & Targeting (DDT) group continued working on the field of nanomedicine, developing novel therapeutic strategies based on biodegradable and natural nanovesicles. In 2021 DDT received funding from 15 projects (7 EU-funded), many of them developed in close collaboration with companies in the BioPharma field. Thanks to intense work, DDT has already become an international reference in use of extracellular vesicles as vehicles for lysosomal enzymes (JEV -IF 25.84), targeted polymeric micelles for delivery of small drugs and biomolecules (JCR, IF 978) and hydrogels for local treatment (MCEC, IF 7.33).
Addressing and proposing solutions for unmet clinical needs is one of our driving forces. Being able to move those solutions from the bench to the bedside, one of our biggest achievements. On 2021, we completed the EU-funded Nocanther project, that brought the first clinical study worldwide to treat locally advanced pancreatic cancer with iron oxide nanoparticles.

Group Leader
Ibane Abasolo

Principal Investigator (PI)
Simó Schwartz, Fernanda Andrade

Guillem Pintos-Morell, Diana Rafael, Joaquin Seras-Franzoso, Vanessa Díaz-Riascos

PhD Students
Patricia González, Sara Montero, Patricia Cámara-Sánchez, Marc Moltó-Abad, Diego Baranda-Martínez

Lab Technicians
Laura García Latorre, Sandra Mancilla Zamora, Belén García Prats, Paula Zamora Pérez, Begoña Fernández Díez

Nursing and Technical Staff
Paula Blanco Vázquez, Julia German Cortes, Maria Pilar Carcavilla Cuartero, Carlos Pavón Regaña, Gregorio L. Casas Martínez, Patricia Rider








Seras-Franzoso J, Díaz-Riascos ZV, Corchero JL, González P, García-Aranda N, Mandaña M, Riera R, Boullosa A, Mancilla S, Grayston A, Moltó-Abad M, Garcia-Fruitós E, Mendoza R, Pintos-Morell G, Albertazzi L, Rosell A, Casas J, Villaverde A, Schwartz S Jr, Abasolo I
Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders
J Extracell Vesicles. 2021 Mar;10(5):e12058
DOI: doi: 10.1002/jev2.12058
IF: 25.84

Fernández Y, Movellan J, Foradada L, Giménez V, García-Aranda N, Mancilla S, Armiñán A, Borgos SE, Hyldbakk A, Bogdanska A, Gobbo OL, Prina-Mello A, Ponti J, Calzolai L, Zagorodko O, Gallon E, Niño-Pariente A, Paul A, Schwartz S Jr, Abasolo I, Vicent MJ
In Vivo Antitumor and Metastatic Efficacy of A polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy
Adv Healthc Mater. 2021 Oct 27:e2101544
DOI: doi: 10.1002/adhm.202101544
IF: 9.93

Andrade F, Rafael D, Vilar-Hernández M, Montero S, Martínez-Trucharte F, Seras-Franzoso J, Díaz-Riascos ZV, Boullosa A, García-Aranda N, Cámara-Sánchez P, Arango D, Nestor M, Abasolo I, Sarmento B, Schwartz S Jr.
Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo
J Control Release. 2021 Mar 10;331:198-212
DOI: doi: 10.1016/j.jconrel.2021.01.022
IF: 9.78

Tomsen-Melero J, Passemard S, García-Aranda N, Díaz-Riascos ZV, González-Rioja R, Nedergaard Pedersen J, Lyngsø J, Merlo-Mas J, Cristóbal-Lecina E, Corchero JL, Pulido D, Cámara-Sánchez P, Portnaya I, Ionita I, Schwartz S Jr, Veciana J, Sala S, Royo M, Córdoba A, Danino D, Pedersen JS, González-Mira E, Abasolo I, Ventosa N
Impact of Chemical Composition on the Nanostructure and Biological Activity of alpha-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment
ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838
DOI: doi: 10.1021/acsami.0c16871
IF: 9.23

Abasolo I, Seras-Franzoso J, Moltó-Abad M, Díaz-Riascos V, Corchero JL, Pintos-Morell G, Schwartz S Jr.
Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1684
DOI: doi: 10.1002/wnan.1684
IF: 9.18

MIMIC-KeY (GA 964386) – A key to the rational design of extracellular vesicles-mimicking nanoparticles
Principal Investigator: Ibane Abasolo
Agency: H2020-FETPROACT-2020.
Funding: 457,250 €
Period: 2021-2025

SafeNMT (GA 814607): Safety testing in the life cycle of nanotechnology-enabled medical technologies for health
Principal Investigator: Ibane Abasolo
Agency: H2020-NMBP2018
Funding: 14,588,286.5 €
Period: 2019-2023

NanoDIRE-CT: Use of Nanobodies as targeted therapy against cancer stem cells
Principal Investigator: Ibane Abasolo
Agency: MICINN – RETOS Program
Funding: 936,045.06 €
Period: 2020-2024

Improved treatment of lysosomal deposition diseases using optimized nanometric vehicles
Principal Investigator: Ibane Abasolo
Agency: Instituto de Salud Carlos iii (ISCiii)
Funding: 116,160 €
Period: 2019-2022

NoCanTher (GA 685795). Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy
Principal Investigator: Simó Schwartz Jr. / Ibane Abasolo
Agency: HORIZON 2020-NMP11-2015
Funding: 7,113,779 €
Period: 2016-2021

Liposomes and its use for enzyme delivery
Priority Number: EP21382062.4
Priority Date: 27/01/2021
Applicants: 16% VHIR / 28% CSIC / 24% CIBER / 16% Nanomol Tech / 16% LeanBio

Cell-penetrating peptides
Priority Number: PCT/EP2021/081100
Priority Date: 09/11/2021
Applicants: 100% VHIR